Figure 7 | Scientific Reports

Figure 7

From: Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab

Figure 7

Differential binding of anti-CD20 obinutuzumab and mutants thereof to CD20. (A) Surface plasmon resonance sensorgram overlays showing binding of obinutuzumab wt (blue), mutant 1 (BHH6-LA/B-kv1) (red) and mutant 2 (BHH6-L/B-kv1) (green) to purified CD20 (400 nM). For setup, please refer to Fig. 5A. (B) Binding to CD20 expressing WSU DLCL2 cells by flow cytometry of obinutuzumab wt (blue), mutant 1 (BHH6-LA/B-kv1) (red) and mutant 2 (BHH6-L/B-kv1) (green).

Back to article page